This activity is designed to meet the educational needs of academic and community oncologists, along with other providers who assist in the management of non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC), and colorectal cancer patients.
This activity will explore the clinical evidence surrounding the role of HER3 in various tumor types.
Upon completion of this activity, participants should be better able to:
- Recognize the role of the HER family, and particularly HER3, in oncogenesis
- Identify the common causes of disease progression in patients with advanced NSCLC, metastatic breast, colorectal, and other cancers, focusing specifically on treatment failure to epidermal growth factor receptor or anti-estrogen-based therapies
- Explain the mechanism of disease of HER3 and HER3-directed antibody drug conjugates (ADCs) under investigation for the treatment of EGFR TKI-resistant NSCLC, breast, and colorectal cancer